文献速递妇科

优化卵巢癌治疗:新辅助化疗联合间歇性肿瘤细胞减灭术与初次肿瘤细胞减灭术在可能切除不理想的上皮性卵巢癌中的比较

Optimizing the treatment of ovarian cancer: Neoadjuvant chemotherapy and interval debulking versus primary debulking surgery for epithelial ovarian cancers likely to have suboptimal resection.
PubMed 文献 · Gynecol Oncol · 2016-12-01

回顾性研究纳入2007年至2013年在Mayo Clinic接受新辅助化疗(NACT)后间歇性肿瘤细胞减灭术(IDS)的IIIC/IV期上皮性卵巢癌患者87例,并将因不可切除而接受NACT/IDS者与接受不理想初次肿瘤细胞减灭术(PDS)者按年龄和分期1:1匹配(各45例)。NACT/IDS组总生存显著优于PDS组(HR 0.53;95%CI 0.32, 0.88),且30天术后Accordion 3/4级并发症更少(11% vs 36%,P=0.01)。

要点

  • NACT/IDS术后中位总生存2.4年,中位无进展生存1.0年。
  • 年龄每增加10岁,总生存 adjusted HR 1.60(95%CI 1.18, 2.16)。
  • IDS前CA-125>35U/mL者总生存 adjusted HR 2.30(95%CI 1.25, 4.23)。

核心结论

  • 年轻和IDS前CA-125正常化与NACT/IDS后生存改善相关。
  • 对于原发上皮性卵巢癌且切除至残留病灶≤1cm可能性低者,NACT/IDS与改善生存和降低围手术期并发症相关。
  • 作者认为这类患者可能最适合NACT/IDS,更可靠的切除性预测指标将有价值。

研究设计与样本

  • 回顾性研究,纳入2007年1月至2013年12月在Mayo Clinic接受NACT后IDS的连续IIIC或IV期上皮性卵巢癌患者87例。
  • 将因不可切除疾病接受NACT/IDS的部分患者与2003年至2011年间接受不理想PDS的患者按年龄和分期1:1匹配(各45例)。
  • 采用Cox比例风险模型估计风险比和95%置信区间。

主要发现

  • 87例NACT/IDS患者术后中位总生存2.4年,中位无进展生存1.0年。
  • 总生存显著更差的因素包括年龄较大(每增加10岁 adjusted HR 1.60,95%CI 1.18, 2.16)和IDS前CA-125升高(CA-125>35U/mL adjusted HR 2.30,95%CI 1.25, 4.23)。
  • 辅助化疗周期数对生存无显著影响。
  • 匹配队列分析(NACT/IDS组 vs 不理想PDS组,各45例)中,NACT/IDS组总生存显著优于PDS组(HR 0.53;95%CI 0.32, 0.88)。
  • NACT/IDS组发生30天术后Accordion 3/4级并发症的患者更少(11% vs 36%,P=0.01)。

临床怎么用

  • 对于原发上皮性卵巢癌且切除至残留病灶≤1cm可能性低者,NACT/IDS与改善生存和降低围手术期并发症相关。
  • 作者认为这类患者可能最适合NACT/IDS。
  • 作者认为更可靠的切除性预测指标将有价值。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To: a) identify prognostic factors in patients with epithelial ovarian cancer treated with neoadjuvant chemotherapy (NACT) and interval debulking surgery (IDS), and b) compare post-surgical survival between patients treated with NACT/IDS for presumed unresectable disease and stage IIIC/IV patients who underwent suboptimal primary debulking surgery (PDS). METHODS: This was a retrospective study of consecutive stage IIIC or IV patients undergoing IDS after NACT at Mayo Clinic from January 2007 to December 2013. A subset of patients receiving NACT/IDS for the indication of unresectable disease were matched 1:1 on age and stage to a cohort of patients who underwent suboptimal PDS between 2003 and 2011. Hazard ratios and corresponding 95% confidence intervals were estimated from Cox proportional hazards models. RESULTS: We identified 87 patients treated with NACT/IDS: the median OS and PFS following surgery was 2.4 and 1.0years, respectively. Factors associated with significantly worse OS were older age (adjusted HR 1.60 per 10-year increase in age, 95% CI 1.18, 2.16) and elevated CA-125 before IDS (adjusted HR 2.30 for CA-125 >35U/mL, 95% CI 1.25, 4.23). Number of adjuvant chemotherapy cycles administered did not have a significant effect on survival. In the matched cohort analysis of presumed unresectable cases undergoing NACT/IDS vs suboptimal PDS cases (n=45 each), the NACT/IDS group had a significant OS advantage (HR 0.53; 95% CI 0.32, 0.88), and fewer patients experienced a 30-day postoperative Accordion grade 3/4 complication (11% vs 36%, P=0.01). CONCLUSIONS: Younger age and normalization of CA-125 prior to IDS are associated with improved survival with NACT/IDS. For primary EOC where resection to residual disease of 1cm or less is unlikely, NACT/IDS is associated with improved survival and reduced perioperative morbidity compared to PDS. As these patients are likely best served by NACT/IDS, more reliable predictors of resectability would be valuable.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Gill SE, McGree ME, Weaver AL, et al. Optimizing the treatment of ovarian cancer: Neoadjuvant chemotherapy and interval debulking versus primary debulking surgery for epithelial ovarian cancers likely to have suboptimal resection. Gynecol Oncol. 2016. PMID: 27916269. doi:10.1016/j.ygyno.2016.11.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。